Editor's note

This ExpertREACT article was originally published on 12 September 2011 following the XVIII Lancefield International Symposium in Palermo, Sicily. Pipeline data and conference highlights described reflect the state of knowledge at that date.

GBS: a leading cause of neonatal meningitis

Group B Streptococcus (GBS, Streptococcus agalactiae) remains a high priority pathogen in Western countries, responsible for more than 85% of bacterial meningitis cases in children under two months according to US 2003-2007 data - exceeding both Streptococcus pneumoniae and Neisseria meningitidis in this age group. GBS incidences were found to be higher than those of Haemophilus influenzae type b prior to that vaccine's introduction - a significant comparator given Hib vaccine's eventual public health impact. The pathogen is also an increasingly important cause of adult disease, with incidence in the 15-64 year age group increasing 48% between 1999 and 2005.

GBS is vertically transmitted from approximately 10-30% of colonised pregnant women during childbirth. Around 50% of neonates are colonised, and approximately 2% of these develop early-onset (EOD, days 0-6) or late-onset (LOD, days 7-89) disease. Historically, EOD incidence ranged from 1 to 3 per 1000 live births - equating to 8-10,000 cases per year in the 1970s - and around 25-50% of survivors of GBS meningitis have permanent neurological sequelae. Despite successive CDC/ACOG/AAP screening and intrapartum antibiotic prophylaxis (IAP) guidelines in 1996 and 2002, the burden of disease has not been fully eliminated.

GBS neonatal meningitis burden
>85%
Of bacterial meningitis cases in children under 2 months in the US (2003-2007 data), exceeding pneumococcal and meningococcal disease

Novartis trivalent GBS vaccine: Phase I results

Novartis Vaccines presented the first significant public update on its trivalent glycoconjugate GBS vaccine composed of serotypes Ia, Ib and III. In a Phase I Belgium study (V98_06), a single 5μg/5μg/5μg dose was shown to be immunogenic (Day 61 GMC, 95% CI) with no benefit from a second dose or alum adjuvant. Novartis predicted its vaccine would cover 65%, 86% and 85% of EOD serotypes in the US, South Africa and Malawi respectively, with higher coverage rates for LOD. The path to licensure was outlined as involving a Phase III efficacy trial of more than 50,000 pregnant women, with epidemiological preparatory studies planned in Hong Kong, the Dominican Republic, Panama and Bangladesh to confirm GBS burden data and inform trial site selection.